^
Association details:
| Biomarker: | ALK-KIF5B fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ensacove (ensartinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Excerpt:
Patients were aged 18 years or older, had stage IIIb or stage IV ALK-positive NSCLC that had progressed while they were on crizotinib therapy....ALK fusion was detected at baseline in 75 (51%) of the 147 patients with assessable responses (table 4). 70 (93%) had an EML4–ALK fusion; variant 1 was the most frequent (table 4). The five non-EML4–ALK fusions were ALK–HIP1 (n=2), ALK–KIF5B (n=1), ALK–PPFIBP1 (n=1), and ALK–DCHS1 (n=1)....Table 4: Efficacy of ensartinib by ALK mutation type...
DOI:
10.1016/S2213-2600(19)30252-8
Trial ID:
